The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune ...

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals ...

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).

Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...

Researchers set out to determine the age groups for which a polygenic risk score would most effectively predict glaucomatous ...

To tackle systemic barriers to eye care, the organization is co-hosting an event titled “No Woman Left Behind – Advancing Eye ...